Updated on 2024/10/18

写真a

 
ODA Kouhei
 
Organization
University Hospital, Medical and Dental Sciences Area University Hospital Clinical Facilities Liver Disease Consultation Center Assistant Professor
Title
Assistant Professor

Degree

  • 博士（医学） ( 2018.2   鹿児島大学 )

Research Interests

  • 肝疾患　脂肪性肝疾患

Research History

  • Kagoshima University   Medical and Dental Hospital, Medical and Dental Sciences Area Medical and Dental Hospital Clinical Facilities Liver Disease Consultation Center   Assistant Professor

    2018.4

  • Kagoshima University   Research Field in Medicine and Health Sciences, Medical and Dental Sciences Area Graduate School of Medical and Dental Sciences Contribution Course HGF Tissue Repair and Regenerative Medicine   Assistant Professor

    2016.2 - 2018.3

Professional Memberships

  • 日本消化器免疫学会

    2014.1

  • 日本超音波医学会

    2012.4

  • 日本インターベンショナルラジオロジー学会

    2012.4

  • 日本消化器内視鏡学会

    2009.3

  • 日本肝臓学会

    2008.4

  • 日本消化器病学会

    2007.10

  • 日本内科学会

    2007.4

▼display all

 

Papers

  • Toyodome A., Mawatari S., Eguchi H., Takeda M., Kumagai K., Taniyama O., Ijuin S., Sakae H., Tabu K., Oda K., Ikeda M., Ido A. .  Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors .  Scientific Reports14 ( 1 ) 16363   2024.12

    　More details

    Language：Japanese   Publisher：Scientific Reports  

    Resistance-associated substitutions (RASs) of hepatitis C virus (HCV) affect the efficacy of direct-acting antivirals (DAAs). In this study, we aimed to clarify the susceptibility of the coexistence of nonstructural (NS) 5A Q24K/L28M/R30Q (or R30E)/A92K RASs, which were observed in patients with DAAs re-treatment failure and to consider new therapeutic agents. We used a subgenomic replicon system in which HCV genotype 1B strain 1B-4 was electroporated into OR6c cells derived from HuH-7 cells (Wild-type [WT]). We converted WT genes to NS5A Q24K/L28M/R30Q/A92K or Q24/L28K/R30E/A92K. Compared with the WT, the Q24K/L28M/R30Q/A92K RASs was 36,000-fold resistant to daclatasvir, 440,000-fold resistant to ledipasvir, 6300-fold resistant to velpatasvir, 3100-fold resistant to elbasvir, and 1.8-fold resistant to pibrentasvir. Compared with the WT, the Q24K/L28M/R30E/A92K RASs was 640,000-fold resistant to daclatasvir and ledipasvir, 150,000-fold resistant to velpatasvir, 44,000-fold resistant to elbasvir, and 1500-fold resistant to pibrentasvir. The Q24K/L28M/R30E/A92K RASs was 816.3 times more resistant to pibrentasvir than the Q24K/L28M/R30Q/A92K RASs. Furthermore, a combination of pibrentasvir and sofosbuvir showed therapeutic efficacy against these RASs. Combination regimens may eradicate HCV with NS5A Q24K/L28M/R30E/A92K RASs.

    DOI： 10.1038/s41598-024-67169-5

    Scopus

    PubMed

  • Sasaki F., Mawatari S., Oda K., Yano H., Maeda H., Tanaka A., Arima S., Kumagai K., Tanoue S., Hashimoto S., Kanmura S., Ido A. .  Usefulness of the aldehyde breath test for predicting metachronous recurrence in patients with esophageal squamous cell carcinoma and hypopharyngeal squamous cell carcinoma .  Esophagus20 ( 4 ) 749 - 756   2023.10

    　More details

    Language：Japanese   Publisher：Esophagus  

    Background: The rate of metachronous recurrence after endoscopic submucosal dissection for early-stage esophageal squamous cell carcinoma and hypopharynx squamous cell carcinoma is as high (10–15%). The acetaldehyde breath test may detect acetaldehyde dehydrogenase 2 gene polymorphisms. Therefore, we evaluated its usefulness in assessing metachronous recurrence in patients with esophageal squamous cell carcinoma and hypopharynx squamous cell carcinoma. Methods: A total of 76 patients underwent endoscopic submucosal dissection for esophageal squamous cell carcinoma and hypopharynx squamous cell carcinoma and were followed up for at least 3 years (non-recurrence group: 52 patients; recurrence group: 24 patients). The risk factors for carcinogenesis were compared between the recurrence and non-recurrence groups, and the acetaldehyde-to-ethanol ratio was assessed. The cutoff acetaldehyde-to-ethanol ratio that correlated with recurrence was established, and the cumulative recurrence rate was evaluated. Results: The recurrence group had a higher acetaldehyde-to-ethanol ratio, daily alcohol consumption, and Lugol-voiding lesion grade than the non-recurrence group in the univariate analysis. The cutoff acetaldehyde-to-ethanol ratio for recurrence was 28.1 based on the receiver operating characteristic curve. The multivariate analysis revealed an acetaldehyde-to-ethanol ratio of > 28.1 and a Lugol-voiding lesion grade associated with carcinogenesis. Patients with an acetaldehyde-to-ethanol ratio of ≥ 28.1 had a significantly high recurrence rate using the Kaplan–Meier method. Conclusions: The acetaldehyde-to-ethanol ratio detected using the acetaldehyde breath test could be a novel biomarker of metachronous recurrence after endoscopic submucosal dissection in patients with esophageal squamous cell carcinoma and hypopharynx squamous cell carcinoma. Trial registration number: UMIN000040615.

    DOI： 10.1007/s10388-023-01024-w

    Scopus

    PubMed

  • Toyodome A., Mawatari S., Taniyama O., Ijuin S., Sakae H., Tabu K., Oda K., Kumagai K., Tasaki T., Ido A. .  A case of acute liver failure due to aggressive natural killer-cell leukemia with a rapid course .  Clinical Journal of Gastroenterology16 ( 3 ) 416 - 421   2023.6

    　More details

    Language：Japanese   Publisher：Clinical Journal of Gastroenterology  

    An 87-year-old man consulted a former doctor with a complaint of black stool and was admitted to hospital because of anemia and multiple gastric ulcers. The laboratory findings showed that his hepatobiliary enzyme levels and inflammatory response were elevated. Computed tomography showed hepatosplenomegaly and enlarged intra-abdominal lymph nodes. Two days later, he was transferred to our hospital due to deterioration of his liver function. Since he had low level of consciousness and his ammonia level was high, we diagnosed him with acute liver failure (ALF) with hepatic coma, and started on-line hemodiafiltration. As the cause of ALF, we suspected hepatic involvement of a hematologic tumor because of high lactate dehydrogenase and soluble interleukin-2 receptor levels and large abnormal lymphocyte-like cells in the peripheral blood. Because of his poor general condition, bone marrow and other histological examinations were difficult, and he died on the third day of hospitalization. Pathological autopsy showed marked hepatosplenomegaly and the proliferation of large abnormal lymphocyte-like cells in the bone marrow, liver, spleen, and lymph nodes. Immunostaining revealed aggressive natural killer-cell leukemia (ANKL). We herein report a rare case of the development of ALF with coma due to ANKL with a review of the relevant literature.

    DOI： 10.1007/s12328-023-01771-4

    Scopus

    PubMed

  • Kumagai K., Mawatari S., Moriuchi A., Oda K., Takikawa Y., Kato N., Oda S., Inoue K., Terai S., Genda T., Shimizu M., Sakaida I., Mochida S., Ido A. .  Early-phase prothrombin time-international normalized ratio in acute liver injury indicates the timing of therapeutic intervention and predicts prognostic improvement .  Hepatology Research53 ( 2 ) 160 - 171   2023.2

    　More details

    Language：Japanese   Publisher：Hepatology Research  

    Aim: We investigated whether an early-phase prothrombin time-international normalized ratio (PT-INR) is an interventional prognostic indicator for patients with acute liver injury, including acute liver failure. Methods: This was a multicenter retrospective observational study. We included 595 patients with alanine aminotransferase levels ≥300 U/L due to acute liver injury who were admitted to Kagoshima University Hospital or other collaborative investigation organizations between January 1, 2010, and December 31, 2015. Patients with alanine aminotransferase levels ≥300 U/L and no previous liver disease were defined as having an acute liver injury. Acute liver failure was defined by PT-INR ≥1.5 with or without hepatic encephalopathy in acute liver injury patients. Data were obtained retrospectively from case reports and analyzed. Results: The PT-INR on day 1 was the most accurate independent prognosis predictor in patients with acute liver injury and acute liver failure. On day 1, the transplant-free survival rates were significantly lower in patients with PT-INR ≥1.3. The transplant-free survival rates were also significantly higher in patients with acute liver injury and acute liver failure, in whom the PT-INR had recovered from ≥1.3 on day 1 to <1.3 by day 8. Conclusion: Early-phase changes in the PT-INR can predict the prognosis of patients with acute liver injury and acute liver failure. Furthermore, PT-INR ≥1.3 could be an interventional marker, whereas PT-INR <1.3 after 1 week could reflect prognostic improvement.

    DOI： 10.1111/hepr.13848

    Scopus

    PubMed

  • Toyodome A., Tamai T., Sasaki F., Hashiguchi M., Taniyama O., Ijuin S., Sakae H., Tabu K., Oda K., Kumagai K., Mawatari S., Ido A. .  Successful Percutaneous Transhepatic Obliteration Plus Sengstaken-Blakemore Tube Combination Therapy for Recurrent Gastroesophageal Variceal Bleeding .  Internal Medicine62 ( 12 ) 1749 - 1755   2023

    　More details

    Language：Japanese   Publisher：Internal Medicine  

    We treated a case of gastroesophageal varices due to decompensated liver cirrhosis associated with Wilson's disease. The varicose veins penetrated the paraesophageal vein. We performed endoscopic variceal ligation (EVL) on the perforating vein and endoscopic injection sclerotherapy distally. However, 5 days after treatment, the patient vomited blood. Esophagogastroduodenoscopy showed bleeding from the ulcer after EVL at the perforating vein. We performed EVL and stopped the bleeding. However, the next day, she vomited blood again and developed hemorrhagic shock. We were able to achieve hemostasis and save the patient's life with combination therapy consisting of percutaneous transhepatic obliteration and Sengstaken- Blakemore tube placement.

    DOI： 10.2169/internalmedicine.0666-22

    Scopus

    PubMed

  • Kumagai K., Kanmura S., Mawatari S., Nakamura Y., Eguchi H., Taniyama O., Toyodome A., Ijuin S., Sakae H., Tabu K., Oda K., Shimata K., Hibi T., Ido A. .  Glycoprotein non-metastatic melanoma protein B expression correlates with the prognosis of acute liver injury/failure .  Frontiers in Cell and Developmental Biology11   1242152   2023

    　More details

    Language：Japanese   Publisher：Frontiers in Cell and Developmental Biology  

    Background: Glycoprotein non-metastatic melanoma protein B (GPNMB) is expressed in macrophages during recovery from acute liver injury (ALI) in carbon tetrachloride (CCl4)-induced liver injury model mice. In this retrospective study, we assessed whether GPNMB levels in the serum and injured liver correlate with liver injury severity and prognosis in patients with ALI or acute liver failure (ALF). Methods: The study involved 56 patients with ALI or ALF who visited the Kagoshima University Hospital. Serum GPNMB level was measured over time, and the localization, proportion, origin, and phenotype of GPNMB-expressing cells in the injured liver were assessed. Finally, the phenotypes of human monocyte-derived macrophages and peripheral blood mononuclear cells (PBMCs) of patients with ALI and ALF were analyzed. Results: Peak GPNMB levels were significantly higher in patients with ALF and hepatic encephalopathy (HE), as well as in those who underwent liver transplantation or died, than in others. The peak GPNMB level correlated with prothrombin activity, prothrombin time-international normalized ratio, Model for End-stage Liver Disease score, and serum hepatocyte growth factor level. GPNMB was expressed in CD68-positive macrophages, and its level increased with the severity of liver injury. The macrophages showed the same polarization as M2c macrophages induced with interleukin-10 from human monocytes. Moreover, PBMCs from patients with ALF exhibited an immunosuppressive phenotype. Conclusion: We found that GPNMB levels in the serum and injured liver, which increased in patients with ALF, especially in those with HE, correlated with the severity of liver injury and prognosis of ALI and ALF. Moreover, GPNMB-positive macrophages exhibited the M2c phenotype. Our results indicate that persistently high GPNMB levels may be a prognostic marker in patients with ALI and ALF.

    DOI： 10.3389/fcell.2023.1242152

    Scopus

    PubMed

  • Mawatari S., Tamai T., Kumagai K., Saisyoji A., Muromachi K., Toyodome A., Taniyama O., Sakae H., Ijuin S., Tabu K., Oda K., Hiramine Y., Moriuchi A., Sakurai K., Kanmura S., Ido A. .  Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma .  Cancers14 ( 24 )   2022.12

    　More details

    Language：Japanese   Publisher：Cancers  

    The present study clarified the prognosis of intermediate-stage hepatocellular carcinoma (HCC) patients who received lenvatinib (LEN) followed by transcatheter arterial chemoembolization (TACE) on demand. We retrospectively evaluated 88 intermediate-stage HCC patients who received LEN. The median age was 74 (range: 47–92) years old, 67 patients were male, and 82 were classified as Child-Pugh A. LEN was administered until disease progression or discontinuation due to adverse events (AEs). The mean duration of LEN treatment was 7.0 months. The response and disease control rates were 51.1% and 89.8%, respectively. The median progression-free survival and overall survival (OS) after the initiation of LEN were 6.8 months and 29.9 months, respectively. The OS in patients for whom LEN was re-administered after TACE (TACE-LEN) was better than that in patients who received other therapies (e.g., only TACE, TACE-other therapy, or only other therapy) even with propensity score matching (p = 0.008). A Cox proportional hazard analysis showed that TACE-LEN was most strongly associated with the OS (hazard ratio: 0.083, 95% confidence interval: 0.019–0.362, p = 0.001). LEN was administered for approximately 11.1 months after TACE. In intermediate-stage HCC patients who can tolerate LEN without discontinuation due to AEs, TACE-LEN may prolong the prognosis.

    DOI： 10.3390/cancers14246139

    Scopus

    PubMed

  • Sakae H., Mawatari S., Oda K., Tabu K., Kumagai K., Mizuno K., Nozuma S., Kitazono I., Kanmura S., Ido A. .  A case of autoimmune hepatitis with thymoma and myasthenia gravis .  Clinical Journal of Gastroenterology15 ( 4 ) 765 - 770   2022.8

    　More details

    Language：Japanese   Publisher：Clinical Journal of Gastroenterology  

    A 44-year-old woman presented with cough, facial edema, and progressive fatigue. Computed tomography (CT) showed an anterior mediastinal mass, and laboratory findings showed liver injury. She was diagnosed with thymoma and scheduled for thymectomy after radiation and chemotherapy. However, she was referred to our department due to exacerbation of liver injury. Autoimmune hepatitis (AIH) was suspected based on the findings of elevated anti-nuclear antibody and immunoglobulin G levels. Histological findings of a liver biopsy confirmed the diagnosis of AIH. After oral steroid therapy initiation, she had diplopia and ptosis. Five days after steroid treatment, bulbar symptoms, such as nasal voice and dysarthria, appeared. A physical examination and electrophysiological tests confirmed myasthenia gravis (MG), and to prevent MG crisis, immunoadsorption plasmapheresis and tacrolimus were started by the neurologist. MG symptoms and liver damage gradually improved, she was then treated with chemotherapy and radiation for thymoma and underwent thymectomy, now showing no relapse of AIH or MG. We report the first case of MG developing immediately after the introduction of prednisolone for AIH complicated with thymoma.

    DOI： 10.1007/s12328-022-01641-5

    Scopus

    PubMed

  • Ijuin S., Oda K., Mawatari S., Taniyama O., Toyodome A., Sakae H., Tabu K., Kumagai K., Kanmura S., Tamai T., Moriuchi A., Uto H., Ido A. .  Serine palmitoyltransferase long chain subunit 3 is associated with hepatocellular carcinoma in patients with nafld .  Molecular and Clinical Oncology16 ( 2 ) 55   2022.2

    　More details

    Language：Japanese   Publisher：Biomedical Reports  

    The prevalence of non-alcoholic fatty liver disease (NAFLD) is continuously increasing, with the proportion of patients with liver carcinogenesis due to non-alcoholic steato-hepatitis (NASH) rising accordingly. Although it is important to identify individuals with hepatic carcinogenesis among patients with NAFLD, useful biomarkers have not yet been established. Previously, in a mouse model of diabetes mellitus without genetic modifications, we reported that a high-fat diet increases serine palmitoyltransferase long chain subunit 3 (SPTLC3) expression in liver tissue, accompanied by high frequency of liver carcinogenesis. Serine palmitoyltransferase (SPT) catalyzes the metabolism of fatty acids, particularly sphingolipid synthesis, and SPTLC3 has been identified as its catalytic subunit, but its role in liver disease is unclear. In the present study, the importance of SPTLC3 in NAFLD development was investigated. SPTLC3 mRNA expression was observed in a liver cancer cell line and in liver tissues from patients with NAFLD and liver cancer. In total, 99 patients with NAFLD (66 without hepatocellular carcinoma (HCC) and 33 with HCC were recruited, having been diagnosed by liver biopsy or imaging, along with 6 healthy volunteers (HVs). Serum was collected from patients and HVs, and SPTLC3 level was assessed by ELISA. SPTLC3 expression was higher in non-cancerous compared with that in cancerous liver tissues. Serum SPTLC3 levels were negatively correlated with platelet count and positively correlated with hyaluronic acid levels, suggesting an association with liver fibrosis. Moreover, SPTLC3 levels were significantly higher in the HCC group than in the HV and NAFLD groups. Multivariate analysis of HCC-related factors identified platelets, alanine transferase, albumin and SPTLC3 as independent factors associated with HCC. Furthermore, in patients with other chronic liver diseases (hepatitis B and C, and alcoholic liver disease), no significant differences in serum SPTLC3 levels were observed between patients with or without HCC. Thus, SPTLC3 expression increases specifically with the progression of NAFLD. Overall, the present results indicate that SPTLC3 may be involved in the development of liver carcinogenesis during NAFLD.

    DOI： 10.3892/mco.2021.2488

    Scopus

    PubMed

  • Mawatari S., Kumagai K., Oda K., Tabu K., Ijuin S., Fujisaki K., Tashima S., Inada Y., Uto H., Saisyoji A., Hiramine Y., Hashiguchi M., Tamai T., Hori T., Taniyama O., Toyodome A., Sakae H., Kure T., Sakurai K., Moriuchi A., Kanmura S., Ido A. .  Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus .  PLoS ONE17 ( 1 January ) e0262267   2022.1

    　More details

    Language：Japanese   Publisher：PLoS ONE  

    Background The features of hepatitis C virus patients with a sustained virologic response (SVR) who developed hepatocellular carcinoma (HCC) after direct-acting antiviral (DAA) therapy are unclear. Methods The study population included 1494 DAA-SVR patients without a history of HCC. The cumulative carcinogenesis rate after the end of treatment (EOT) and factors related to HCC were analyzed. Results Sixty (4.0%) patients developed HCC during a median observation period of 47.6 months. At four years, the cumulative carcinogenesis rate was 4.7%. A Cox proportional hazards analysis showed that age 73 years (hazard ratio [HR]: 2.148), male sex (HR: 3.060), hyaluronic acid (HA) 75 ng/mL (HR: 3.996), alpha-fetoprotein at EOT (EOT-AFP) 5.3 ng/mL (HR: 4.773), and albumin at EOT (EOT-Alb) <3.9 g/dL (HR: 2.305) were associated with HCC development. Especially, EOT-AFP 5.3 ng/mL was associated with HCC development after 3 years from EOT (HR: 6.237). Among patients who developed HCC, AFP did not increase in patients with EOT-AFP <5.3 ng/mL at the onset of HCC. Of these 5 factors, EOT-AFP 5.3 ng/mL was scored as 2 points; the others were scored as 1 point. The 4-year cumulative carcinogenesis rate for patients with total scores of 0–2, 3–4, and 5–6 points were 0.6%, 11.9%, and 27.1%, respectively (p<0.001). Conclusions EOT-AFP 5.3 ng/mL is useful for predicting HCC development after an SVR. However, AFP does not increase in patients with EOT-AFP <5.3 ng/mL at the onset of HCC. The combination of EOT-AFP, age, sex, HA, and EOT-Alb is important for predicting carcinogenesis.

    DOI： 10.1371/journal.pone.0262267

    Scopus

    PubMed

  • Tabu K., Mawatari S., Oda K., Taniyama O., Toyodome A., Ijuin S., Sakae H., Kumagai K., Kanmura S., Ido A. .  Highly sensitive lens culinaris agglutinin-reactive fraction of α-fetoprotein is a predictive marker for hepatocarcinogenesis in long-term observation of patients with chronic liver disease .  Molecular and Clinical Oncology15 ( 3 ) 174   2021.9

    　More details

    Language：Japanese   Publisher：Molecular and Clinical Oncology  

    Highly sensitive Lens culinaris agglutinin-reactive fraction of α-fetoprotein (hs-AFP-L3) is a specific marker for hepatocellular carcinoma (HCC) and has been reliable in cases with a low serum α-fetoprotein (AFP) level. However, the biomarkers that contribute to hepatocarcinogenesis during the long-term observation are not yet clear. The present study reported the clinical utility of hs-AFP-L3 in the long-term observation of patients with chronic liver disease. The subjects were 106 patients with chronic liver disease without HCC or a history of HCC treatment and who had been followed for >12 months. hs-AFP-L3 was measured using cryopreserved serum. The factors contributing to hepatocarcinogenesis were examined using univariate and multivariate analyses. The median observation period was 88 months (15-132 months). The cumulative incidence of HCC was 10.5% at 5 years and 19.6% at 10 years. The univariate analysis revealed that age ≥55 years old, platelet count ≤13.1x104/µl, hyaluronic acid ≥80.8 ng/ml, alanine transaminase ≥47 U/l, AFP ≥6.3 ng/ml, hs-AFP-L3 ≥3.5% and des-γ-carboxy prothrombin (DCP) ≥25 mAU/ml were significant factors. In the multivariate analysis, platelet count ≤13.1x104/µl [hazard ratio (HR), 4.966; 95% confidence interval (CI), 1.597-15.437; P=0.006] and hs-AFP-L3 ≥3.5% (HR, 5.450; 95% CI, 1.522-19.512; P=0.009) were extracted as significant factors contributing to hepatocarcinogenesis. In addition, for cases with AFP <20 ng/ml, a multivariate analysis revealed that hs-AFP-L3 ≥4.9% (HR, 11.608; 95% CI, 2.422-55.629; P=0.002) and DCP ≥25 mAU/ml (HR, 3.936; 95% CI, 1.088-14.231; P=0.037) were significant factors contributing to hepatocarcinogenesis. hs-AFP-L3 is a useful marker for predicting hepatocarcinogenesis in the long-term observation of patients with chronic liver disease.

    DOI： 10.3892/mco.2021.2336

    Scopus

    PubMed

  • Sasaki F., Kanmura S., Oda K., Maeda H., Kabayama M., Iwaya H., Komaki Y., Arima S., Tanoue S., Hashimoto S., Fujita H., Ido A. .  Acetaldehyde breath test as a cancer risk marker in patients with esophageal and hypopharyngeal squamous cell carcinoma .  PLoS ONE16 ( 5 May ) e0251457   2021.5

    　More details

    Language：Japanese   Publisher：PLoS ONE  

    Patients with inactive acetaldehyde dehydrogenase 2 (ALDH2) are at high risk for esophageal squamous cell carcinoma (ESCC) and hypopharyngeal squamous cell carcinoma (HPSCC). The acetaldehyde breath test (ABT) may demonstrate ALDH2 gene polymorphisms. We evaluated the usefulness of the ABT in patients with ESCC and HPSCC. The squamous cell carcinoma (SCC) group consisted of 100 patients who were treated with endoscopic submucosal dissection (ESD) for ESCC or HPSCC, and the control group (HC) consisted of 275 healthy subjects. The SCC group comprised the "single subgroup"(n = 63), in which a single lesion was initially treated with ESD, and the "multiple subgroup"(n = 31), in which multiple lesions were initially treated with ESD. First, we compared the groups' risk factors for carcinogenesis and measured the acetaldehyde-to-ethanol (A/E) ratio. Then we tested the groups' differences in the abovementioned carcinogenic risk factors. We found that the proportion of individuals in the SCC group with inactive ALDH2 (A/E ratio ≥ 23.3) was significantly higher than that in the HC group (p = 0.035), as was the A/E ratio (p < 0.001). Also, the proportion of individuals with inactive ALDH2 in the multiple subgroup was significantly higher than that in single subgroup (p = 0.015), as was the A/E ratio (p = 0.008). In conclusion, ABT may be a potential screening tool for detecting people at risk of ESCC and HPSCC. In addition, it could be a useful tool in detecting patients at risk of multiple or double carcinomas among patients with ESCC and HPSCC.

    DOI： 10.1371/journal.pone.0251457

    Scopus

    PubMed

  • Imamura Y. .  Changes in body composition and low blood urea nitrogen level related to an increase in the prevalence of fatty liver over 20 years: A cross-sectional study .  Hepatology Research51 ( 5 ) 570 - 579   2021

    　More details

    Language：Japanese   Publisher：Hepatology Research  

    Aim: Qualitative body composition (BC) change, characterized by the combination of visceral fat gain and muscle loss, is drawing attention as a risk factor for fatty liver (FL). The present study aimed to describe trends in BC change and its association with FL in the Japanese population. Methods: Data from medical checkups carried out on 56 639 Japanese participants every 5 years from 1997 to 2017 were analyzed. Fat mass index (FMI) and fat-free mass index (FFMI) were calculated using body mass index and body fat percentage. Subjects were divided into two groups according to deviations from the correlation line of FMI and FFMI as the reference: FMI-predominant BC and FFM-dominant BC. Fatty liver was determined using abdominal ultrasonography. Results: The prevalence of FL significantly increased from 27.3% to 42.7% in men and from 18.0% to 25.5% in women. The prevalence of FMI predominance significantly increased from 33.6% to 43.9% in men and from 29.1% to 47.0% in women. Fat mass index predominance was independently associated with FL in men and women (odds ratio: 1.96 and 1.94, respectively). Serum blood urea nitrogen level was inversely associated with FL in men and women (0.958 and 0.961, respectively) and significantly decreased from 15.8 to 14.9 mg/dl in men and from 15.1 to 14.0 mg/dl in women. Conclusions: Increasing FMI-predominant BC and decreasing serum blood urea nitrogen level could account for the increase in the prevalence of FL over 20 years. We believe that these factors stem from current lifestyle habits in Japan.

    DOI： 10.1111/hepr.13631

    Scopus

    PubMed

  • Kazuaki Tabu, Seiichi Mawatari, Kohei Oda, Kotaro Kumagai, Yukiko Inada, Hirofumi Uto, Akiko Saisyoji, Yasunari Hiramine, Masafumi Hashiguchi, Tsutomu Tamai, Takeshi Hori, Kunio Fujisaki, Dai Imanaka, Takeshi Kure, Ohki Taniyama, Ai Toyodome, Sho Ijuin, Haruka Sakae, Kazuhiro Sakurai, Akihiro Moriuchi, Shuji Kanmura, Akio Ido .  Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals .  PLoS One15 ( 8 ) e0237475   2020Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antiviralsReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Seiichi Mawatari, Kohei Oda, Kotaro Kumagai, Kazuaki Tabu, Sho Ijuin, Kunio Fujisaki, Yukiko Inada, Hirofumi Uto, Akiko Saisyoji, Yasunari Hiramine, Takeshi Hori, Ohki Taniyama, Ai Toyodome, Haruka Sakae, Masafumi Hashiguchi, Takeshi Kure, Kazuhiro Sakurai, Tsutomu Tamai, Akihiro Moriuchi, Akio Ido .  Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all-oral direct antiviral therapy .  Hepatology Research50 ( 4 ) 453 - 465   2020Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all-oral direct antiviral therapyReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Nao Nishikoba, Kotaro Kumagai, Shuji Kanmura, Yuko Nakamura, Mayumi Ono, Hiromi Eguchi, Tomomi Kamibayashiyama, Kohei Oda, Seiichi Mawatari, Shiroh Tanoue, Shinichi Hashimoto, Hirohito Tsubouchi, Akio Ido .  HGF-MET Signaling Shifts M1 Macrophages Toward an M2-Like Phenotype Through PI3K-Mediated Induction of Arginase-1 Expression .  Frontiers in Immunology2 ( 11 ) 2135   2020HGF-MET Signaling Shifts M1 Macrophages Toward an M2-Like Phenotype Through PI3K-Mediated Induction of Arginase-1 ExpressionReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Nobuhiro Hiraishi, Shuji Kanmura, Kouhei Oda, Shiho Arima, Kotaro Kumagai, Seiichi Mawatari, Shiroh Tanoue, Fumisato Sasaki, Shinichi Hashimoto, Akio Ido .  Extract of Lactobacillus plantarum strain 06CC2 induces JNK/p38 MAPK pathway-mediated apoptosis through endoplasmic reticulum stress in Caco2 colorectal cancer cells .  Biochemistry and Biophysics Reports   2019.12Extract of Lactobacillus plantarum strain 06CC2 induces JNK/p38 MAPK pathway-mediated apoptosis through endoplasmic reticulum stress in Caco2 colorectal cancer cellsReviewed

  • Ohki Taniyama, Seiichi Mawatari, Kohei Oda, Kazuaki Tabu, Sho Ijuin, Kotaro Kumagai, Ai Kasai, Shuzo Tashima, Tsutomu Tamai, Akihiro Moriuchi, Akio Ido .  Sustained virologic response after eight weeks of treatment with sofosbuvir, ledipasvir, and ribavirin in a decompensated cirrhotic patient with hepatitis C virus genotype 1b .  Hepatology Research49 ( 2 ) 239 - 243   2019Sustained virologic response after eight weeks of treatment with sofosbuvir, ledipasvir, and ribavirin in a decompensated cirrhotic patient with hepatitis C virus genotype 1bReviewed

  • Yuga Komaki, Shuji Kanmura, Fumisato Sasaki, Hidehito Maeda, Kohei Oda, Shiho Arima, Shiroh Tanoue, Yuichiro Nasu, Shinichi Hashimoto, Seiichi Mawatari, Hirohito Tsubouchi, Akio Ido .  Hepatocyte Growth Factor Facilitates Esophageal Mucosal Repair and Inhibits the Submucosal Fibrosis in a Rat Model of Esophageal Ulcer .  Digestion99 ( 3 ) 227 - 238   2019Hepatocyte Growth Factor Facilitates Esophageal Mucosal Repair and Inhibits the Submucosal Fibrosis in a Rat Model of Esophageal UlcerReviewed

  • Takeshi Kure, Seiichi Mawatari, Yasushi Imamura, Kohei Oda, Kotaro Kumagai, Yasunari Hiramine, Hironori Miyahara, Shuji Kanmura, Akihiro Moriuchi, Hirofumi Uto, Masahisa Horiuchi, Akio Ido .  Nonalcoholic fatty liver disease is associated with both subcutaneous and visceral adiposity: A cross-sectional study .  Medicine (Baltimore)98 ( 46 ) e17879   2019Nonalcoholic fatty liver disease is associated with both subcutaneous and visceral adiposity: A cross-sectional studyReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Tamai T, Taniyama O, Oda K, Kasai A, Ijyuin S, Sakae H, Onishi H, Tabu K, Kumagai K, Mawatari S, Moriuchi A, Uto H, Ido A. .  Reduction effect of the quantity of radiation exposure and contrast media by image support system in transarterial chemoembolization contributes to reduction of the quantity of radiation exposure and contrast media. .  Journal of Gastroenterology and Hepatology33 ( 5 ) 1115 - 1122   2018Reduction effect of the quantity of radiation exposure and contrast media by image support system in transarterial chemoembolization contributes to reduction of the quantity of radiation exposure and contrast media.Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Seiichi Mawatari, Akihiro Moriuchi, Fuminori Ohba, Tetsu Kawano, Kohei Oda, Yasuhiro Takikawa, Hajime Takikawa, Akio Ido, Hirohito Tsubouchi .  The recovery of the PT-INR to less than 1.3 predicts survival in patients with severe acute liver injury .  Journal of Gastroenterology53 ( 7 ) 861 - 872   2018The recovery of the PT-INR to less than 1.3 predicts survival in patients with severe acute liver injuryReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Seiichi Mawatari, Kohei Oda, Kazuaki Tabu, Sho Ijuin, Kotaro Kumagai, Kunio Fujisaki, Masafumi Hashiguchi, Yukiko Inada, Hirofumi Uto, Yasunari Hiramine, Takeshi Kure, Takeshi Hori, Oki Taniyama, Ai Kasai, Tsutomu Tamai, Akihiro Moriuchi, Akio Ido .  The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir .  PLoS One13 ( 6 ) e0198642   2018The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvirReviewed

  • Mawatari S, Oda K, Tabu K, Ijuin S, Kumagai K, Inada Y, Uto H, Hiramine Y, Kure T, Fujisaki K, Hashiguchi M, Hori T, Oshige A, Imanaka D, Saishoji A, Taniyama O, Sakae H, Tamai T, Moriuchi A, Ido A. .  New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir. .  Journal of Gastroenterology   2017New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s00535-016-1303-0.

  • Tamai T, Oshige A, Tabu K, Tabu E, Ijyuin S, Sakae H, Onishi H, Muromachi K, Saisyoji A, Oda K, Kumagai K, Mawatari S, Moriuchi A, Sakurai K, Hori T, Ido A. .  Utility of percutaneous radiofrequency ablation alone or combined with transarterial chemoembolization for early hepatocellular carcinoma. .  Oncology Letters   2017Utility of percutaneous radiofrequency ablation alone or combined with transarterial chemoembolization for early hepatocellular carcinoma.

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Ibusuki R, Uto H, Oda K, Ohshige A, Tabu K, Mawatari S, Kumagai K, Kanmura S, Tamai T, Moriuchi A, Tsubouchi H, Ido A. .  Human neutrophil peptide-1 promotes alcohol-induced hepatic fibrosis and hepatocyte apoptosis. .  PLoS One   2017Human neutrophil peptide-1 promotes alcohol-induced hepatic fibrosis and hepatocyte apoptosis.Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Ono Y, Kanmura S, Morinaga Y, Oda K, Kawabata K, Arima S, Sasaki F, Nasu Y, Tanoue S, Hashimoto S, Taguchi H, Uto H, Tsubouchi H, Ido A. .  The utility of apoptosis inhibitor of macrophages as a possible diagnostic marker in patients with Crohn's disease. .  BMC Gastroenterology   2017The utility of apoptosis inhibitor of macrophages as a possible diagnostic marker in patients with Crohn's disease.Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Tsutomu Tamai, Kotaro Kumagai, Haruka Sakae, Hiroka Onishi, Kazuaki Tabu, Eriko Tabu, Kaori Muromachi, Akiko Saishoji, Kohei Oda, Seiichi Mawatari, Akihiro Moriuchi, Kazuhiro Sakurai, Akio Ido .  Early sorafenib induction after transarterial chemoembolization for unresectable hepatocellular carcinoma: Can sorafenib after TACE improve loco-regional control ? .  Molecular and Clinical Oncology7 ( 6 ) 1135 - 1141   2017Early sorafenib induction after transarterial chemoembolization for unresectable hepatocellular carcinoma: Can sorafenib after TACE improve loco-regional control ?Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Kozono M, Uto H, Ibusuki R, Arima S, Oda K, Taguchi H, Sasaki F, Nasu Y, Hashimoto S, Setoyama H, Kanmura S, Numata M, Tsubouchi H, Ido A. .  Antihypertensive therapy improves insulin resistance and serum levels of interleukin-6 and -10 in spontaneously hypertensive rats with steatohepatitis. .  Molecular Medicine Reports   2016Antihypertensive therapy improves insulin resistance and serum levels of interleukin-6 and -10 in spontaneously hypertensive rats with steatohepatitis.Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Kanmura S, Hamamoto H, Morinaga Y, Oda K, Fujita T, Arima S, Nasu Y, Sasaki F, Hashimoto S, Taguchi H, Setoyama H, Ido A. .  Fecal Human Neutrophil Peptide Levels Correlate with Intestinal Inflammation in Ulcerative Colitis. .  Digestion   2016Fecal Human Neutrophil Peptide Levels Correlate with Intestinal Inflammation in Ulcerative Colitis.Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Hiramine Y, Uto H, Imamura Y, Hiwaki T, Kure T, Ijuin S, Oda K, Mawatari S, Kumagai K, Tokunaga K, Higashi H, Kanetsuki I, Kubozono O, Maenohara S, Ido A. .  Efficacy of vasopressin V2 receptor antagonist tolvaptan in treatment of hepatic edema. .  Hepatology Research   2016Efficacy of vasopressin V2 receptor antagonist tolvaptan in treatment of hepatic edema.Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Mawatari S, Uto H, Moriuchi A, Tabu K, Muromachi K, Tabu E, Oda K, Imanaka D, Oshige A, Nakazawa J, Kumagai K, Tamai T, Okamoto H, Tsubouchi H, Ido A. .  Horizontal transmission of de novo hepatitis B between spouses: A case report. .  Hepatology Research   2015Horizontal transmission of de novo hepatitis B between spouses: A case report.Invited Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Kohei Oda, Hirofumi Uto, Seiichi Mawatari, Akio Ido .  Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies .  Clinical Journal of Gastroenterology8 ( 1 ) 1 - 9   2015Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studiesReviewed

    　More details

    Authorship：Lead author   Language：English  

  • Arima S, Uto H, Ibusuki R, Kumamoto R, Tanoue S, Mawatari S, Oda K, Numata M, Fujita H, Oketani M, Ido A, Tsubouchi H. .  Hypertension exacerbates liver injury and hepatic fibrosis induced by a choline-deficient L-amino acid-defined diet in rats. .  International Journal of Molecular Medicine   2014Hypertension exacerbates liver injury and hepatic fibrosis induced by a choline-deficient L-amino acid-defined diet in rats.Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Oda K, Uto H, Kumagai K, Ido A, Kusumoto K, Shimoda K, Hayashi K, Stuver SO, Tanaka Y, Nishida N, Tokunaga K, Tsubouchi H. .  Impact of a single nucleotide polymorphism upstream of the IL28B gene in patients positive for anti-HCV antibody in an HCV hyperendemic area in Japan. .  Journal of Medical Virology   2014Impact of a single nucleotide polymorphism upstream of the IL28B gene in patients positive for anti-HCV antibody in an HCV hyperendemic area in Japan.Reviewed

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  • Tokunaga M, Uto H, Oda K, Tokunaga M, Mawatari S, Kumagai K, Haraguchi K, Oketani M, Ido A, Ohnou N, Utsunomiya A, Tsubouchi H. .  Influence of human T-lymphotropic virus type 1 coinfection on the development of hepatocellular carcinoma in patients with hepatitis C virus infection. .  Journal of Gastroenterology   2014Influence of human T-lymphotropic virus type 1 coinfection on the development of hepatocellular carcinoma in patients with hepatitis C virus infection.Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Mera K, Uto H, Mawatari S, Ido A, Yoshimine Y, Nosaki T, Oda K, Tabu K, Kumagai K, Tamai T, Moriuchi A, Oketani M, Shimada Y, Hidaka M, Eguchi S, Tsubouchi H. .  Serum levels of apoptosis inhibitor of macrophage are associated with hepatic fibrosis in patients with chronic hepatitis C. .  BMC Gastroenterology   2014Serum levels of apoptosis inhibitor of macrophage are associated with hepatic fibrosis in patients with chronic hepatitis C.Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Kumamoto R, Uto H, Oda K, Ibusuki R, Tanoue S, Arima S, Mawatari S, Kumagai K, Numata M, Tamai T, Moriuchi A, Fujita H, Oketani M, Ido A, Tsubouchi H. .  Dietary fructose enhances the incidence of precancerous hepatocytes induced by administration of diethylnitrosamine in rat. .  European Journal of Medical Research   2013Dietary fructose enhances the incidence of precancerous hepatocytes induced by administration of diethylnitrosamine in rat.Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Mawatari S, Uto H, Ido A, Nakashima K, Suzuki T, Kanmura S, Kumagai K, Oda K, Tabu K, Tamai T, Moriuchi A, Oketani M, Shimada Y, Sudoh M, Shoji I, Tsubouchi H. .  Hepatitis C virus NS3/4A protease inhibits complement activation by cleaving complement component 4. .  PLoS One   2013Hepatitis C virus NS3/4A protease inhibits complement activation by cleaving complement component 4.

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Oda K, Ido A, Tamai T, Matsushita M, Kumagai K, Mawatari S, Saishoji A, Kure T, Ohno K, Toyokura E, Imanaka D, Moriuchi A, Uto H, Oketani M, Hashiguchi T, Tsubouchi H. .  Highly sensitive lens culinaris agglutinin-reactive α-fetoprotein is useful for early detection of hepatocellular carcinoma in patients with chronic liver disease. .  Oncology Reports   2011Highly sensitive lens culinaris agglutinin-reactive α-fetoprotein is useful for early detection of hepatocellular carcinoma in patients with chronic liver disease.Reviewed

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  • Tamai T, Uto H, Takami Y, Oda K, Saishoji A, Hashiguchi M, Kumagai K, Kure T, Mawatari S, Moriuchi A, Oketani M, Ido A, Tsubouchi H. .  Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for hepatitis C virus-related hepatocellular carcinoma. .  World Journal of Gastroenterology   2011Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for hepatitis C virus-related hepatocellular carcinoma.Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

▼display all

MISC

  • 【脂肪肝の新概念:MASLD】MASHの病態　MASLDと酸化ストレス

    小田 耕平

    臨床消化器内科   39 ( 7 )   773 - 778   2024.6

    　More details

    Language：Japanese   Publisher：(株)日本メディカルセンター  

    ＜文献概要＞ウイルス性肝炎(B型肝炎,C型肝炎)に対する治療が大きく進歩したことが肝疾患診療に与えたインパクトは大きく,肝硬変や肝癌のおもな成因もウイルス性肝炎から非ウイルス性肝炎(非B非C)へと変遷している.非ウイルス性肝炎の多くは,生活習慣(飲酒,過栄養,運動不足)に起因するものであり,脂肪性肝疾患(SLD)が多くを占める.代謝異常に関連するSLDの新たな疾患概念としてMASLDが提唱されたが,MASLDは全身疾患であり,その病態進展に関わる因子の一つとして酸化ストレスが挙げられる.酸化ストレスはMASLDの肝合併症の進行において重要であるとともに,MASLDの生命予後に大きく関わる心・脳血管疾患や糖尿病,腎臓病とも深く関連する.MASLD患者の生命予後改善には酸化ストレスに着目した検査や治療介入が有効である可能性が期待される.

  • 【内部障害のリハビリテーション医学・医療の進歩】肝臓リハビリテーションの進歩

    小田 耕平, 井戸 章雄

    The Japanese Journal of Rehabilitation Medicine   58 ( 10 )   1120 - 1127   2021.10

    　More details

    Language：Japanese   Publisher：(公社)日本リハビリテーション医学会  

    ウイルス性肝炎が制御可能となり、肝硬変・肝がんの原因疾患としてNAFLD/NASHの占める割合が増加している。NAFLD/NASHに対する薬物療法は確立しておらず、運動療法は非常に重要な役割を担っている。NASHの生命予後改善のためには、肝脂肪化や線維化の改善を期待し、7～10%程度の体重減少を目標とする。運動療法の目標として、"週3回以上、合計150分程度の中等度(3METs)以上の有酸素運動"と"週2～3回程度のレジスタンス運動"を組み合わせることが挙げられる。NASH肝硬変ではサルコペニアや脳・心血管疾患の合併頻度が高く、これらの病態の改善にも運動療法が寄与することが期待される。(著者抄録)

  • 各都道府県における肝疾患対策取り組みの現状　鹿児島県における肝炎対策の現状

    小田 耕平, 尻無濱 君代, 山西 真太郎, 椨 一晃, 熊谷 公太郎, 馬渡 誠一, 井戸 章雄

    肝臓クリニカルアップデート   7 ( 1 )   110 - 113   2021.10

    　More details

    Language：Japanese   Publisher：医学図書出版(株)  

  • 【肝疾患エキスパートブック　栄養管理に活かすための最新情報】(Part 3)NAFLD/NASH　NAFLD/NASHに対する運動療法の実際

    小田 耕平, 井戸 章雄

    臨床栄養   139 ( 4 )   545 - 549   2021.9

    　More details

    Language：Japanese   Publisher：医歯薬出版(株)  

    ＜Key Point＞・NAFLD/NASH患者は急増しているが、薬物療法は確立しておらず保険適応がある薬剤も存在しない。食事や運動療法による減量が肥満合併NAFLD/NASHに対する治療の第一選択である。・体重の7%以上の減量が推奨され、10%以上の減量では、NAFLD/NASH患者の予後を規定する肝線維化の改善が期待できる。・運動療法の目標として、「週3回以上、合計150分程度の中強度(3 METs)以上の運動」と、「週2～3回程度のレジスタンス運動」を組み合わせることがあげられる。・運動アドヒアランスの向上のためには、個別の運動指導のほか、医師のみでなく、看護師、栄養士、薬剤師や健康運動指導士などによるチームによる多面的な介入が必要である。(著者抄録)

  • 【糖尿病とNAFLD/NASH】DKDとNAFLD

    吉嶺 陽仁, 小田 耕平, 井戸 章雄

    月刊糖尿病   13 ( 7 )   43 - 47   2021.7

    　More details

    Language：Japanese   Publisher：(株)医学出版  

  • 【肝臓リハビリテーションUpdate】NAFLD/NASH患者のリハビリテーション

    小田耕平、井戸章雄

    Journal of Clinical Rehabilitation   29 ( 1 )   20 - 26   2020

    　More details

    Authorship：Lead author   Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

  • 漢方製剤（筋痙攣、肝庇護）

    小田耕平、井戸章雄

    肝硬変診療マニュアル   215 - 217   2019

    　More details

    Authorship：Lead author   Language：Japanese  

  • 【肝癌治療のイノベーション-シミュレーション・ナビゲーション技術の新展開-】TACE　肝細胞癌に対する肝動脈化学塞栓療法における血管造影装置の進歩

    玉井 努, 椨 一晃, 小田 耕平, 熊谷 公太郎, 馬渡 誠一, 森内 昭博, 堀 剛, 坪内 博仁, 井戸 章雄

    肝胆膵   77 ( 6 )   1219 - 1226   2018

    　More details

    Publisher：(株)アークメディア  

  • 肝不全治療薬　肝不全用アミノ酸製剤，成分栄養剤

    小田耕平，井戸章雄

    肝疾患治療マニュアル   2017

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

  • 【肝臓を診る-肝臓病のキモ】肝不全・肝硬変・肝細胞がん　急性肝不全　致死的経過となるリスクの見極めとその後の対応

    小田 耕平, 井戸 章雄

    内科   119 ( 6 )   1163 - 1167   2017

    　More details

    Publisher：(株)南江堂  

    正常肝に肝障害が生じ,8週間以内に高度の肝機能障害に基づいてプロトロンビン時間が40%以下ないしはINR値が1.5以上を示すものを急性肝不全と定義する.成因には肝炎によるものと肝炎以外によるものがあり成因や病型によって治療法や予後が異なる.急性肝不全は内科救命率がきわめて低く,感染症やDICなど多臓器にわたる合併症を併発するため厳重な全身管理を要する.近年では発症年齢の高齢化により基礎疾患を複数有する症例も多く,全身管理の重要性が増している.肝移植のみが唯一救命率を向上させる治療法であり,非専門医療機関においてはPT値等を適切に評価し,専門医療機関への移送の時機を逸せぬよう注意する.(著者抄録)

  • 【急性肝不全】急性肝不全治療薬HGFの臨床開発

    井戸 章雄, 森内 昭博, 小田 耕平, 馬渡 誠一, 玉井 努, 坪内 博仁

    ICUとCCU   41 ( 10 )   631 - 636   2017

    　More details

    Publisher：医学図書出版(株)  

    肝細胞増殖因子(HGF)は肝再生を強力に促進する増殖因子で、抗アポトーシス、抗繊維化作用などの多彩な作用を併せ持っている。われわれは長年、組換えヒトHGFの医薬品化に取り組み、2005年に劇症肝炎を対象とした第I/II相臨床試験を医師主導治験の枠組みで実施した。本臨床試験では劇症肝炎患者4例に組換えヒトHGFを反復静脈内投与したが、重篤な有害事象はみられなかった。その後、製薬企業の協力を得てJST研究成果最適展開支援プログラムA-STEP本格研究開発ステージ実用化挑戦タイプ「組換えヒト肝細胞増殖因子を用いた急性肝不全の治療」に採択され、新たに製造した組換えヒトHGFを用いて臨床開発を推進している。(著者抄録)

  • 劇症肝炎と肝不全

    井戸章雄、小田耕平

    Annual Review 消化器2016   2016

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

  • NAFLD・NASH

    小田耕平、宇都浩文

    Medicina   2014

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

  • de novo B型肝炎の予防ガイドラインは機能したか？

    小田耕平、宇都浩文、井戸章雄

    肝胆膵   2014

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

  • NAFLD/NASHの診断および肝発癌ハイリスク群の拾い上げをどう行うか

    宇都浩文、小田耕平、井戸章雄

    消化器の臨床   2014

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

  • 意識障害の原因疾患と対応 肝疾患

    小田耕平、井戸章雄、坪内博仁

    臨床と研究   2013

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

  • バイオマーカー

    小田耕平、宇都浩文

    Hepatology Practice Vol.2   2013

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

  • 急性肝炎・劇症肝炎

    井戸章雄、小田耕平

    Hepatology Practice Vol.1   2013

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

  • NAFLD/NASH の疾患概念

    小田耕平、宇都浩文、坪内博仁

    臨牀消化器内科   2013

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

▼display all

Presentations

  • Sho Ijyuin, Kohei Oda, Tsutomu Tamai, Seiichi Mawatari, Nobuhiro Hiraishi, Haruka Sakae, Hiroka Onishi, Kazuaki Tabu, Akihiro Moriuchi, Hirofumi Uto, Akio Ido   The association between serum levels of Sptlc3 and the clinical features of patients with NAFLD   International conference

    •APASL 2017 

    　More details

    Event date： 2017.4

    Language：English   Presentation type：Poster presentation  

  • Kohei Oda, Hirofumi Uto, Yoshio Sumida, Takeshi Okanoue, Seiichi Mawatari, Rie Ibusuki, Syo Ijyuin, Hiroka Onishi, Haruka Sakae, Kaori Muromachi, Eriko Tabu, Akihiko Oshige, Tsutomu Tamai, Akihiro Moriuchi, Hirohito Tsubouchi, Akio Ido.   The association between serum levels of apoptosis inhibitor of macrophage (AIM) and the clinical features of non-obese patients with nonalcoholic fatty liver disease.   International conference

    APASL 2016 

    　More details

    Event date： 2016.2

    Language：English   Presentation type：Poster presentation  

  • Kohei Oda, Hirofumi Uto, Seiichi Mawatari, Rie Ibusuki, Sho Ijyuin, Hiroka Onishi, Haruka Sakae, Kaori Muromachi, Akihiko Oshige, Kotaro Kumagai, Tsutomu Tamai, Akihiro Moriuchi, Akio Ido.   Serum levels of Wisteria floribunda agglutinin?positive human Mac-2 binding protein are useful for evaluating early liver fibrosis in hepatitis C patients.   International conference

    AASLD The Liver Meeting 2015 

    　More details

    Event date： 2015.11

    Language：English   Presentation type：Poster presentation  

  • Kohei Oda, Hirofumi Uto, Yoshio Sumida, Takeshi Okanoue, Seiichi Mawatari, Hiroka Onishi, Haruka Sakae, Kaori Muromachi, Eriko Tabu, Akihiko Oshige, Dai Imanaka, Tsutomu Tamai, Akihiro Moriuchi, Hirohito Tsubouchi, Akio Ido.   Serum levels of apoptosis inhibitor of macrophage (AIM) are associated with hepatic fibrosis and insulin resistance in patients with nonalcoholic fatty liver disease.   International conference

    AASLD The Liver Meeting 2014 

    　More details

    Event date： 2014.11

    Language：English   Presentation type：Poster presentation  

  • Kohei Oda, Hirofumi Uto, Seiichi Mawatari, Kazuaki Tabu, Kaori Ohno, Eriko Toyokura, Akihiko Oshige, Dai Imanaka, Kotaro Kumagai, Tsutomu Tamai, Akihiro Moriuchi, Makoto Oketani, Akio Ido, Yoshio Sumida, Hirohito Tsubouchi.   The association between serum levels of apoptosis inhibitor of macrophage and the clinical features of nonalcoholic fatty liver disease.   International conference

    AASLD The Liver Meeting 2013 

    　More details

    Event date： 2013.11

    Language：English   Presentation type：Poster presentation  

  • Kohei Oda, Hirofumi Uto, Naoko Tsubouchi, Kotaro Kumagai, Fumisato Sasaki, Masatsugu Numata, Akihiro Moriuchi, Makoto Oketani, Akio Ido, Kazunori Kusumoto, Kazuya Shimoda, Katsuhiro Hayashi, Sherri O. Stuver, Yasuhito Tanaka, Nao Nishida, Katsushi Tokunaga, Hirohito Tsubouchi.   Impact of a single nucleotide polymorphism upstream of the IL28B gene in subjects positive for anti-HCV antibody in an HCV hyperendemic area in Japan.   International conference

    AASLD The Liver Meeting 2012 

    　More details

    Event date： 2012.11

    Language：English   Presentation type：Poster presentation  

  • 室町 香織, 森内 昭博, 伊集院 翔, 大西 容雅, 坂江 遥, 大重 彰彦, 小田 耕平, 馬渡 誠一, 玉井 努, 平峯 靖也, 桜井 一宏, 井戸 章雄   鹿児島県におけるA型急性肝炎流行時の急性肝不全例の特徴  

    肝臓  2017.6  (一社)日本肝臓学会

  • 馬渡 誠一, 玉井 努, 最勝寺 晶子, 谷山 央樹, 豊留 亜衣, 坂江 遥, 椨 一晃, 小田 耕平, 熊谷 公太郎, 平峯 靖也, 桜井 一宏, 井戸 章雄   進行肝癌に対するレンバチニブの至適導入時期の検討  

    肝臓  2020.4  (一社)日本肝臓学会

  • 豊留 亜衣, 馬渡 誠一, 谷山 央樹, 伊集院 翔, 坂江 遥, 椨 一晃, 小田 耕平, 熊谷 公太郎, 井戸 章雄   重症型アルコール性肝炎に対しステロイドが奏功し,全身管理を継続し救命しえた1例  

    日本消化器病学会九州支部例会プログラム・抄録集  2020.6  日本消化器病学会-九州支部

  • 灰床 裕介, 谷山 央樹, 馬渡 誠一, 樺山 雅之, 豊留 亜衣, 伊集院 翔, 坂江 遥, 椨 一晃, 小田 耕平, 熊谷 公太郎, 井戸 章雄   高アンモニア血症を伴った十二指腸憩室出血に対し経カテーテル動脈塞栓術(IVR)が著効した一例  

    日本消化器病学会九州支部例会プログラム・抄録集  2020.6  日本消化器病学会-九州支部

  • 椨 一晃, 馬渡 誠一, 小田 耕平, 笠井 亜衣, 伊集院 翔, 玉井 努, 森内 昭博, 井戸 章雄   高感度AFP-L3%は肝発癌の予測マーカーである  

    肝臓  2018.9  (一社)日本肝臓学会

  • 椨 一晃, 馬渡 誠一, 豊留 亜衣, 谷山 央樹, 伊集院 翔, 坂江 遥, 小田 耕平, 熊谷 公太郎, 井戸 章雄   高感度AFP-L3分画はDAA療法後の肝発癌を予測する有用なマーカーである  

    肝臓  2020.9  (一社)日本肝臓学会

  • 馬渡 誠一, 玉井 努, 最勝寺 晶子, 谷山 央樹, 笠井 亜衣, 坂江 遥, 伊集院 翔, 椨 一晃, 小田 耕平, 熊谷 公太郎, 平峯 靖也, 井戸 章雄   進行肝癌に対するレンバチニブの至適導入時期の検討  

    日本消化器病学会雑誌  2020.7  (一財)日本消化器病学会

  • 大井 貴之, 笠井 亜衣, 馬渡 誠一, 田嶋 修三, 伊集院 翔, 坂江 遥, 椨 一晃, 小田 耕平, 熊谷 公太郎, 森内 昭博, 井戸 章雄   自己免疫性好中球減少症の合併が疑われた自己免疫性肝炎の1例  

    日本消化器病学会九州支部例会プログラム・抄録集  2019.5  日本消化器病学会-九州支部

  • 伊集院 翔, 小田 耕平, 笠井 亜衣, 椨 一晃, 熊谷 公太郎, 馬渡 誠一, 玉井 努, 森内 昭博, 宇都 浩文, 井戸 章雄   自己免疫性肝炎急性期におけるshear wave elastographyの臨床的意義の検討  

    肝臓  2018.9  (一社)日本肝臓学会

  • 伊集院 翔, 小田 耕平, 笠井 亜衣, 谷山 央樹, 坂江 遙, 椨 一晃, 熊谷 公太郎, 馬渡 誠一, 森内 昭博, 宇都 浩文, 井戸 章雄   自己免疫性肝炎急性期の肝硬度測定の意義と再燃との関連の検討  

    肝臓  2019.10  (一社)日本肝臓学会

  • 仮屋 遥香, 豊留 亜衣, 谷山 央樹, 伊集院 翔, 坂江 遥, 椨 一晃, 小田 耕平, 熊谷 公太郎, 馬渡 誠一, 井戸 章雄   診断に苦慮した胆管細胞癌の1例  

    肝臓  2020.11  (一社)日本肝臓学会

  • 嶋田 淳之介, 豊留 亜衣, 小牧 祐雅, 湯通堂 和樹, 樺山 雅之, 小田 耕平, 馬渡 誠一, 田ノ上 史郎, 上村 修司, 井戸 章雄   腸重積を契機に発見された回腸異所性膵の1例  

    日本消化器病学会九州支部例会プログラム・抄録集  2020.6  日本消化器病学会-九州支部

  • 今村 也寸志, 馬渡 誠一, 小田 耕平, 細山田 香, 伊集院 大生, 平峯 靖也, 最勝寺 晶子, 井戸 章雄   脂肪肝に見られる量的・質的変容について  

    糖尿病  2019.4  (一社)日本糖尿病学会

  • 寺田 芳寛, 田嶋 修三, 笠井 亜衣, 伊集院 翔, 椨 一晃, 小田 耕平, 熊谷 公太郎, 馬渡 誠一, 森内 昭博, 井戸 章雄   腸腰筋膿瘍に対しCTガイド下ドレナージ術が奏功し救命し得たAcute on chronic型肝不全の1例  

    日本消化器病学会九州支部例会プログラム・抄録集  2018.11  日本消化器病学会-九州支部

  • 馬渡 誠一, 玉井 努, 田嶋 修三, 笠井 亜衣, 伊集院 翔, 椨 一晃, 小田 耕平, 熊谷 公太郎, 森内 昭博, 井戸 章雄   肝腫瘍のトータルマネジメント　切除不能肝細胞癌に対するレンバチニブの治療成績  

    日本消化器病学会九州支部例会プログラム・抄録集  2019.5  日本消化器病学会-九州支部

  • 今村 也寸志, 宇都 浩文, 馬渡 誠一, 平峯 靖也, 小田 耕平, 最勝寺 晶子, 井戸 章雄   生活習慣病と肝疾患　脂肪肝における世代間の違いについて  

    日本消化器病学会九州支部例会プログラム・抄録集  2018.11  日本消化器病学会-九州支部

  • 柴田 隆佑, 笠井 亜衣, 馬渡 誠一, 田嶋 修三, 伊集院 翔, 椨 一晃, 小田 耕平, 熊谷 公太郎, 森内 昭博, 井戸 章雄   甲状腺中毒症に薬物性肝障害を合併した急性肝不全の一例  

    日本消化器病学会九州支部例会プログラム・抄録集  2018.11  日本消化器病学会-九州支部

  • 最勝寺 晶子, 桜井 一宏, 西田 紀子, 小田 耕平, 玉井 努, 井戸 章雄   糖尿病合併NAFLD患者に対するSGLT2阻害薬の治療効果の検討  

    肝臓  2017.11  (一社)日本肝臓学会

  • 谷山 央樹, 馬渡 誠一, 豊留 亜衣, 伊集院 翔, 坂江 遥, 椨 一晃, 小田 耕平, 熊谷 公太郎, 井戸 章雄   肝がん治療の最前線　肝細胞癌(HCC)に対するバイポーラ針を用いた経皮的ラジオ波焼灼術(RFA)の安全性と有効性についての検討  

    日本消化器病学会九州支部例会プログラム・抄録集  2020.6  日本消化器病学会-九州支部

  • 豊留 亜衣, 馬渡 誠一, 谷山 央樹, 伊集院 翔, 坂江 遥, 椨 一晃, 小田 耕平, 熊谷 公太郎, 井戸 章雄   肝動脈化学塞栓療法におけるエマルション薬液調整用コネクタの初期使用経験  

    肝臓  2020.9  (一社)日本肝臓学会

  • 金丸 紗千, 谷山 央樹, 馬渡 誠一, 豊留 亜衣, 伊集院 翔, 坂江 遥, 椨 一晃, 小田 耕平, 熊谷 公太郎, 井戸 章雄   肝外転移を伴った肝細胞癌に対し集学的治療で長期生存が得られた一例  

    日本消化器病学会九州支部例会プログラム・抄録集  2020.12  日本消化器病学会-九州支部

  • 小田 耕平, 佐々木 文郷, 井戸 章雄   肝疾患に対する非侵襲的診断法の進歩　アルデヒド呼気テストによる非侵襲的アルコール代謝能評価の有用性の検討  

    肝臓  2019.11  (一社)日本肝臓学会

  • 森内 昭博, 小田 耕平, 井戸 章雄   肝硬変の成因別実態　当科における肝硬変の成因別実態  

    肝臓  2018.4  (一社)日本肝臓学会

  • 谷山 央樹, 玉井 努, 最勝寺 晶子, 伊集院 翔, 坂江 遥, 大西 容雅, 椨 恵理子, 椨 一晃, 大重 彰彦, 小田 耕平, 馬渡 誠一, 森内 昭博, 桜井 一宏, 堀 剛, 井戸 章雄   肝細胞癌(HCC)に対するバイポーラ針を用いた経皮的ラジオ波焼灼術(RFA)の安全性と有効性についての検討  

    肝臓  2017.4  (一社)日本肝臓学会

  • 小田 耕平, 佐々木 文郷, 田島 修三, 笠井 亜衣, 伊集院 翔, 椨 一晃, 熊谷 公太郎, 馬渡 誠一, 森内 昭博, 藤田 浩, 井戸 章雄   生活習慣病と肝疾患　慢性肝疾患診療におけるアルデヒド呼気テストの有用性の検討  

    日本消化器病学会九州支部例会プログラム・抄録集  2018.11  日本消化器病学会-九州支部

  • 豊留 亜衣, 小田 耕平, 谷山 央樹, 伊集院 翔, 大西 容雅, 坂江 遥, 椨 一晃, 室町 香織, 熊谷 公太郎, 馬渡 誠一, 宇都 浩文, 井戸 章雄   施設内感染が疑われたB型急性肝炎の3症例  

    肝臓  2019.11  (一社)日本肝臓学会

  • 熊谷 公太郎, 森内 昭博, 小田 耕平, 馬渡 誠一, 井戸 章雄   当科における薬物性急性肝不全の特徴  

    肝臓  2021.2  (一社)日本肝臓学会

  • 玉井 努, 谷山 央樹, 伊集院 翔, 坂江 遥, 椨 一晃, 小田 耕平, 馬渡 誠一, 森内 昭博, 井戸 章雄   当科における非B非C型肝細胞癌の臨床的特徴に関する検討  

    肝臓  2017.9  (一社)日本肝臓学会

  • 井戸 章雄, 森内 昭博, 小田 耕平, 坪内 博仁   急性肝不全の集中治療　肝再生を目指したHGFの臨床開発  

    日本集中治療医学会雑誌  2017.2  (一社)日本集中治療医学会

  • 伊集院 翔, 馬渡 誠一, 田嶋 修三, 笠井 亜衣, 谷山 央樹, 坂江 遥, 椨 一晃, 小田 耕平, 熊谷 公太郎, 森内 昭博, 井戸 章雄   急速な腫瘍内壊死を呈し、レンバチニブが奏功した肝細胞癌の一例  

    日本消化器病学会九州支部例会プログラム・抄録集  2019.5  日本消化器病学会-九州支部

  • 伊集院 翔, 小田 耕平, 谷山 央樹, 豊留 亜衣, 坂江 遥, 椨 一晃, 熊谷 公太郎, 馬渡 誠一, 井戸 章雄   慢性肝疾患患者における皮膚そう痒症の臨床学的特徴  

    肝臓  2020.9  (一社)日本肝臓学会

  • 伊集院 翔, 小田 耕平, 田嶋 修三, 笠井 亜衣, 坂江 遥, 椨 一晃, 熊谷 公太郎, 馬渡 誠一, 森内 昭博, 井戸 章雄   慢性肝疾患診療におけるサルコペニアの現状  

    日本消化器病学会雑誌  2019.3  (一財)日本消化器病学会

  • 馬渡 誠一, 谷山 央樹, 伊集院 翔, 坂江 遥, 椨 一晃, 小田 耕平, 玉井 努, 森内 昭博, 井戸 章雄   当科におけるソホスブビル+レジパスビル療法の成績  

    日本消化器病学会雑誌  2017.3  (一財)日本消化器病学会

  • 森内 昭博, 小田 耕平, 井戸 章雄   当県における肝炎医療コーディネーター養成の現状  

    肝臓  2019.4  (一社)日本肝臓学会

  • 小田 耕平, 尻無濱 君代, 椨 一晃, 熊谷 公太郎, 馬渡 誠一, 井戸 章雄   当県における肝炎医療コーディネーター養成の現状と課題  

    肝臓  2020.4  (一社)日本肝臓学会

  • 椨 一晃, 小田 耕平, 馬渡 誠一, 笠井 亜衣, 伊集院 翔, 坂江 遥, 玉井 努, 森内 昭博, 井戸 章雄   当科で経験した骨髄性プロトポルフィリン症の4例  

    肝臓  2017.11  (一社)日本肝臓学会

  • 佐々木 文郷, 小田 耕平, 有馬 志穂, 那須 雄一郎, 田ノ上 史郎, 橋元 慎一, 上村 修司, 湯通堂 和樹, 軸屋 賢一, 藤田 浩, 井戸 章雄   咽頭癌・食道癌における呼気中微量アセトアルデヒド/エタノール測定の有用性の検討  

    日本消化器病学会雑誌  2018.10  (一財)日本消化器病学会

  • 佐々木 文郷, 小田 耕平, 有馬 志穂, 那須 雄一郎, 田ノ上 史郎, 橋元 慎一, 上村 修司, 藤田 浩, 井戸 章雄   咽頭癌・食道癌ESD患者における呼気中微量アセトアルデヒド/エタノール測定の有用性の検討  

    日本消化器病学会雑誌  2019.3  (一財)日本消化器病学会

  • 佐々木 文郷, 小田 耕平, 井戸 章雄   呼気中微量アセトアルデヒド/エタノール測定は、咽頭・食道扁平上皮癌診断の新たなバイオマーカーとして有用である  

    日本消化器病学会雑誌  2020.7  (一財)日本消化器病学会

  • 小田 耕平, 佐々木 文郷, 笠井 亜衣, 伊集院 翔, 椨 一晃, 馬渡 誠一, 熊谷 公太郎, 玉井 努, 森内 昭博, 藤田 浩, 井戸 章雄   呼気中微量アセトアルデヒド/エタノール測定の慢性肝疾患診療における有用性の検討  

    肝臓  2018.4  (一社)日本肝臓学会

  • 玉井 努, 馬渡 誠一, 笠井 亜衣, 谷山 央樹, 伊集院 翔, 椨 一晃, 小田 耕平, 熊谷 公太郎, 森内 昭博, 坪内 博仁, 井戸 章雄   切除不能進行肝細胞癌(HCC)に対するSorafenib不応後の集学的治療に関する検討  

    The Liver Cancer Journal  2018.12  (株)メディカルレビュー社

  • 佐々木 文郷, 小田 耕平, 井戸 章雄   アルデヒド呼気試験は、咽頭食道扁平上皮癌の重複・多重患者を非侵襲的に抽出する  

    日本食道学会学術集会プログラム・抄録集  2020.12  (NPO)日本食道学会

  • 馬渡 誠一, 谷山 央樹, 伊集院 翔, 坂江 遥, 椨 一晃, 小田 耕平, 玉井 努, 森内 昭博, 井戸 章雄   インターフェロンフリー治療不成功例の薬剤耐性変異の検討  

    日本消化器病学会雑誌  2017.3  (一財)日本消化器病学会

  • 馬渡 誠一, 森内 昭博, 谷山 央樹, 伊集院 翔, 坂江 遥, 椨 一晃, 小田 耕平, 玉井 努, 井戸 章雄   インターフェロンフリー治療不成功例の薬剤耐性変異解析  

    肝臓  2017.4  (一社)日本肝臓学会

  • 馬渡 誠一, 豊留 亜衣, 谷山 央樹, 伊集院 翔, 坂江 遥, 椨 一晃, 小田 耕平, 熊谷 公太郎, 井戸 章雄   インターフェロンフリー療法後の新規発癌例の検討  

    肝臓  2020.4  (一社)日本肝臓学会

  • 馬渡 誠一, 玉井 努, 谷山 央樹, 伊集院 翔, 坂江 遥, 椨 一晃, 小田 耕平, 森内 昭博, 井戸 章雄   インターフェロンフリー療法後の発癌例の検討  

    肝臓  2017.4  (一社)日本肝臓学会

  • 馬渡 誠一, 森内 昭博, 田嶋 修三, 笠井 亜衣, 伊集院 翔, 椨 一晃, 小田 耕平, 熊谷 公太郎, 井戸 章雄   ウイルス性肝炎の残された課題と対策　インターフェロンフリー療法再治療の実態と治療効果  

    日本消化器病学会九州支部例会プログラム・抄録集  2018.11  日本消化器病学会-九州支部

  • 伊比 裕太郎, 伊集院 翔, 小田 耕平, 田嶋 修三, 笠井 亜衣, 椨 一晃, 熊谷 公太郎, 馬渡 誠一, 森内 昭博, 井戸 章雄   シスプラチンを用いたTACE後に著明な低Na血症をきたした胆管細胞癌の1例  

    日本消化器病学会九州支部例会プログラム・抄録集  2018.11  日本消化器病学会-九州支部

  • 伊集院 翔, 小田 耕平, 熊谷 公太郎, 馬渡 誠一, 谷山 央樹, 豊留 亜衣, 坂江 遥, 椨 一晃, 宇都 浩文, 井戸 章雄   スフィンゴ脂質代謝酵素SPTLC3とNASH肝発癌との関連の検討  

    肝臓  2020.4  (一社)日本肝臓学会

  • 伊集院 翔, 小田 耕平, 玉井 努, 馬渡 誠一, 笠井 亜衣, 谷山 央樹, 大西 容雅, 坂江 遙, 椨 一晃, 室町 香織, 森内 昭博, 宇都 浩文, 井戸 章雄   スフィンゴ脂質代謝酵素SPTLC3のNAFLD診療における有用性の検討  

    日本消化器病学会雑誌  2018.3  (一財)日本消化器病学会

  • 田嶋 修三, 笠井 亜衣, 伊集院 翔, 椨 一晃, 小田 耕平, 熊谷 公太郎, 馬渡 誠一, 森内 昭博, 井戸 章雄   健常成人に発症したサイトメガロウイルス感染症に脾梗塞を合併した1例  

    日本消化器病学会九州支部例会プログラム・抄録集  2018.11  日本消化器病学会-九州支部

  • 小田 耕平, 佐々木 文郷, 笠井 亜衣, 伊集院 翔, 椨 一晃, 熊谷 公太郎, 馬渡 誠一, 森内 昭博, 藤田 浩, 井戸 章雄   健診受診者におけるアルデヒド呼気試験の有用性の検討  

    糖尿病  2019.4  (一社)日本糖尿病学会

  • 馬渡 誠一, 玉井 努, 笠井 亜衣, 伊集院 翔, 椨 一晃, 小田 耕平, 熊谷 公太郎, 森内 昭博, 井戸 章雄   切除不能肝細胞癌に対する分子標的治療薬有効例の検討  

    肝臓  2019.10  (一社)日本肝臓学会

  • 小田 耕平, 佐々木 文郷, 井戸 章雄   アルデヒド呼気テストの肝疾患診療における有用性の検討  

    肝臓  2019.4  (一社)日本肝臓学会

  • 東 大智, 伊集院 翔, 小田 耕平, 田嶋 修三, 笠井 亜衣, 椨 一晃, 熊谷 公太郎, 馬渡 誠一, 森内 昭博, 井戸 章雄   TAEにて腫瘍縮小が得られた頭蓋内血管外皮腫の肝転移の1例  

    日本消化器病学会九州支部例会プログラム・抄録集  2018.11  日本消化器病学会-九州支部

  • 宮之前 優香, 伊集院 翔, 小田 耕平, 馬渡 誠一, 笠井 亜衣, 谷山 央樹, 坂江 遙, 椨 一晃, 熊谷 公太郎, 井戸 章雄   S状結腸膿瘍の血行性散布と考えられた多発細菌性肝膿瘍の一例  

    日本消化器病学会九州支部例会プログラム・抄録集  2019.11  日本消化器病学会-九州支部

  • 馬渡 誠一, 玉井 努, 最勝寺 晶子, 豊留 亜衣, 谷山 央樹, 坂江 遥, 伊集院 翔, 椨 一晃, 橋口 正史, 小田 耕平, 熊谷 公太郎, 井戸 章雄   BCLC intermediate-stageに対するレンバチニブ投与の有用性の検討  

    肝臓  2020.9  (一社)日本肝臓学会

  • 椨 一晃, 馬渡 誠一, 田嶋 修三, 笠井 亜衣, 伊集院 翔, 小田 耕平, 熊谷 公太郎, 森内 昭博, 井戸 章雄   C型肝炎ウイルスの再感染後に自然消失が疑われた1例  

    日本消化器病学会九州支部例会プログラム・抄録集  2018.11  日本消化器病学会-九州支部

  • 笠井 亜衣, 馬渡 誠一, 田嶋 修三, 伊集院 翔, 椨 一晃, 小田 耕平, 熊谷 公太郎, 森内 昭博, 井戸 章雄   C型肝炎治療前後におけるShear Wave Elastographyの有用性の検討  

    日本消化器病学会雑誌  2019.3  (一財)日本消化器病学会

  • 谷山 央樹, 馬渡 誠一, 豊留 亜衣, 伊集院 翔, 坂江 遥, 椨 一晃, 小田 耕平, 熊谷 公太郎, 井戸 章雄   C型非代償性肝硬変患者に対するソホスブビルベース治療の有効性と安全性の検討  

    肝臓  2020.4  (一社)日本肝臓学会

  • 小田 耕平, 笠井 亜衣, 谷山 央樹, 伊集院 翔, 大西 容雅, 坂江 遥, 椨 一晃, 室町 香織, 熊谷 公太郎, 馬渡 誠一, 森内 昭博, 宇都 浩文, 井戸 章雄   FIB-4外来の有効性とその課題について  

    日本消化器病学会雑誌  2019.11  (一財)日本消化器病学会

  • 笠井 亜衣, 馬渡 誠一, 田嶋 修三, 伊集院 翔, 椨 一晃, 小田 耕平, 熊谷 公太郎, 森内 昭博, 井戸 章雄   Genotype3b型のC型代償性肝硬変に対しグレカプレビル/ピブレンタスビルを投与し、ウイルスの再燃を認めた1例  

    日本消化器病学会九州支部例会プログラム・抄録集  2018.11  日本消化器病学会-九州支部

  • 豊留 亜衣, 馬渡 誠一, 谷山 央樹, 伊集院 翔, 坂江 遥, 椨 一晃, 小田 耕平, 熊谷 公太郎, 井戸 章雄   GLE/PIB治療不成功例の検討  

    肝臓  2020.4  (一社)日本肝臓学会

  • 伊集院 翔, 小田 耕平, 玉井 努, 馬渡 誠一, 谷山 央樹, 大西 容雅, 坂江 遥, 椨 一晃, 森内 昭博, 宇都 浩文, 井戸 章雄   NASH肝発癌におけるスフィンゴ脂質代謝酵素SPTLC3の検討  

    糖尿病  2017.4  (一社)日本糖尿病学会

  • 伊集院 翔, 小田 耕平, 玉井 努, 馬渡 誠一, 笠井 亜衣, 谷山 央樹, 大西 容雅, 坂江 遥, 椨 一晃, 森内 昭博, 宇都 浩文, 井戸 章雄   NASH肝発癌におけるスフィンゴ脂質代謝酵素Sptlc3の検討  

    肝臓  2017.9  (一社)日本肝臓学会

  • 伊集院 翔, 小田 耕平, 井戸 章雄   NASH診療の現状と問題点　スフィンゴ脂質代謝酵素SPTLC3はNASHの肝発癌に関連する  

    肝臓  2017.4  (一社)日本肝臓学会

  • 馬渡 誠一, 森内 昭博, 谷山 央樹, 坂江 遥, 伊集院 翔, 椨 一晃, 小田 耕平, 玉井 努, 井戸 章雄   SOF/LDV治療不成功に関連する因子の検討  

    肝臓  2017.9  (一社)日本肝臓学会

▼display all

Awards

  • 鹿児島県医師会医学研究助成

    2016.6   鹿児島県医師会  

    小田耕平

    　More details

    Country：Japan

  • 日本肝臓学会冠Award 第14回 MSD Award

    2015.10   日本肝臓学会  

    小田耕平

    　More details

    Award type：Award from Japanese society, conference, symposium, etc.  Country：Japan